GBP2’s anti-tumor effects in breast cancer hinge on mitochondrial dynamics and autophagy, while its pro-tumor role in glioblastoma leverages fibronectin remodeling and Stat3 activation, reflecting TME-specific signaling [31,36]. Here, FN1 is linked to glioblastoma.